Envestnet Asset Management Inc. increased its holdings in LivaNova PLC (NASDAQ:LIVN) by 17.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,493 shares of the company’s stock after buying an additional 1,824 shares during the quarter. Envestnet Asset Management Inc.’s holdings in LivaNova were worth $922,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Maverick Capital Ltd. boosted its holdings in shares of LivaNova by 21.4% in the second quarter. Maverick Capital Ltd. now owns 71,240 shares of the company’s stock worth $5,126,000 after buying an additional 12,580 shares during the last quarter. Oakbrook Investments LLC purchased a new position in shares of LivaNova in the second quarter worth approximately $245,000. Bank of Montreal Can boosted its holdings in shares of LivaNova by 332.1% in the second quarter. Bank of Montreal Can now owns 22,843 shares of the company’s stock worth $1,643,000 after buying an additional 17,557 shares during the last quarter. Ontario Teachers Pension Plan Board purchased a new position in shares of LivaNova in the second quarter worth approximately $3,336,000. Finally, Atria Investments LLC purchased a new position in shares of LivaNova in the second quarter worth approximately $478,000. 88.74% of the stock is currently owned by institutional investors.
In other LivaNova news, CEO Damien Mcdonald sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $73.70, for a total transaction of $73,700.00. Also, Director Daniel Jeffrey Moore sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $84.56, for a total transaction of $126,840.00. In the last 90 days, insiders have sold 8,000 shares of company stock worth $634,715. 0.41% of the stock is owned by company insiders.
A number of equities analysts recently issued reports on LIVN shares. BTIG Research reissued a “hold” rating on shares of LivaNova in a report on Wednesday, July 31st. Needham & Company LLC dropped their price objective on shares of LivaNova from $91.00 to $88.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. ValuEngine raised shares of LivaNova from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research downgraded shares of LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, BidaskClub raised shares of LivaNova from a “sell” rating to a “hold” rating in a report on Thursday. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $97.67.
NASDAQ LIVN opened at $73.33 on Friday. LivaNova PLC has a 12 month low of $64.80 and a 12 month high of $126.99. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of 23.13, a PEG ratio of 3.36 and a beta of 0.53. The company’s 50 day moving average is $73.26 and its two-hundred day moving average is $74.32. The company has a current ratio of 1.17, a quick ratio of 0.81 and a debt-to-equity ratio of 0.21.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, October 30th. The company reported $0.84 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.09. LivaNova had a negative net margin of 20.35% and a positive return on equity of 9.44%. The company had revenue of $268.60 million for the quarter, compared to analysts’ expectations of $273.41 million. During the same quarter last year, the business earned $0.78 EPS. The firm’s revenue was down 1.3% compared to the same quarter last year. Sell-side analysts forecast that LivaNova PLC will post 2.69 EPS for the current year.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.